HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kristoffer Hellstrand Selected Research

Histamine (Histamine Dihydrochloride)

1/2020Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
2/2019Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
1/2019NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
1/2018Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.
1/2018Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.
11/2017Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.
1/2017Role of NOX2-Derived Reactive Oxygen Species in NK Cell-Mediated Control of Murine Melanoma Metastasis.
1/2016Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
12/2015NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
5/2015Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kristoffer Hellstrand Research Topics

Disease

24Infections
10/2022 - 12/2004
21Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 07/2006
15Neoplasms (Cancer)
01/2022 - 01/2002
12Chronic Hepatitis C
06/2014 - 10/2006
11Melanoma (Melanoma, Malignant)
12/2020 - 01/2002
11Leukemia
01/2019 - 07/2006
6Neoplasm Metastasis (Metastasis)
12/2020 - 09/2004
5COVID-19
10/2022 - 01/2022
5Virus Diseases (Viral Diseases)
01/2022 - 12/2004
3Fibrosis (Cirrhosis)
07/2022 - 01/2008
3Pathologic Complete Response
11/2019 - 07/2006
2Multiple Sclerosis
01/2022 - 08/2009
2B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
12/2020 - 05/2016
2Carcinogenesis
11/2020 - 12/2004
2Hematologic Neoplasms (Hematological Malignancy)
05/2016 - 08/2011
2Glioblastoma (Glioblastoma Multiforme)
02/2015 - 11/2013
2Guillain-Barre Syndrome
08/2010 - 12/2007
1Hematologic Diseases (Blood Diseases)
10/2022
1Liver Diseases (Liver Disease)
07/2022
1B-Cell Lymphoma (Lymphoma, B Cell)
12/2020
1Coinfection
11/2020
1Hepatitis D
11/2020
1Hemolytic Anemia
10/2018
1Lymphoma (Lymphomas)
05/2015
1Anemia
06/2014
1Thrombocytopenia (Thrombopenia)
06/2014
1Insulin Resistance
09/2012
1Obesity
01/2012
1Postpoliomyelitis Syndrome (Post-Polio Syndrome)
12/2010
1Liver Cirrhosis (Hepatic Cirrhosis)
01/2008
1Autoimmune Diseases (Autoimmune Disease)
12/2007

Drug/Important Bio-Agent (IBA)

25Histamine (Histamine Dihydrochloride)FDA Link
01/2020 - 01/2002
20Interleukin-2 (IL2)IBA
01/2020 - 01/2002
16Ribavirin (Virazole)FDA LinkGeneric
10/2018 - 10/2006
13InterferonsIBA
10/2022 - 10/2006
11RNA (Ribonucleic Acid)IBA
01/2022 - 08/2007
10Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022 - 06/2002
5Immunoglobulin G (IgG)IBA
10/2022 - 01/2018
5CytokinesIBA
01/2022 - 06/2002
5Antiviral Agents (Antivirals)IBA
09/2012 - 12/2004
4DNA (Deoxyribonucleic Acid)IBA
01/2022 - 02/2015
3Proteins (Proteins, Gene)FDA Link
07/2022 - 10/2006
3NADPH Oxidases (NAD(P)H oxidase)IBA
05/2015 - 12/2007
3Interferon-alpha (Interferon Alfa)IBA
12/2004 - 01/2003
2COVID-19 VaccinesIBA
10/2022 - 01/2022
2Peptides (Polypeptides)IBA
10/2022 - 01/2022
2AntigensIBA
07/2022 - 02/2016
2VaccinesIBA
07/2022 - 01/2022
2Messenger RNA (mRNA)IBA
07/2022 - 02/2015
2EnzymesIBA
01/2022 - 01/2022
2Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2022 - 11/2020
2AntibodiesIBA
01/2022 - 07/2011
2ChemokinesIBA
01/2020 - 01/2013
2Histamine H2 ReceptorsIBA
01/2019 - 12/2012
2Inosine TriphosphataseIBA
10/2018 - 06/2014
2Biomarkers (Surrogate Marker)IBA
01/2013 - 08/2011
2peginterferon alfa-2a (Pegasys)FDA Link
08/2010 - 08/2007
12019-nCoV Vaccine mRNA-1273IBA
10/2022
1Amino AcidsFDA Link
10/2022
1BNT162 VaccineIBA
10/2022
1Hepatitis B e AntigensIBA
01/2022
1Adenosine (Adenocard)FDA LinkGeneric
01/2022
1Surface Antigens (Surface Antigen)IBA
01/2022
1GuanineIBA
01/2022
1Interleukin-1beta (Interleukin 1 beta)IBA
01/2021
1Natural Killer Cell ReceptorsIBA
01/2021
1idelalisibIBA
12/2020
1Phosphotransferases (Kinase)IBA
12/2020
1Chemokine ReceptorsIBA
01/2020
1Melphalan (Alkeran)FDA LinkGeneric
01/2020
1Cytarabine (Cytosar-U)FDA LinkGeneric
11/2019
1AnthracyclinesIBA
11/2019
1Daunorubicin (Cerubidine)FDA LinkGeneric
11/2019
1LigandsIBA
02/2019
1Interferon LambdaIBA
01/2019
1HLA-B Antigens (HLA-B)IBA
01/2019
1Antineoplastic Agents (Antineoplastics)IBA
01/2017
1Monoclonal AntibodiesIBA
05/2016
14- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA
05/2015
1PyrophosphatasesIBA
06/2014
1Inosine Triphosphate (ITP)IBA
06/2014
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2014
1ValganciclovirFDA Link
11/2013
1InterleukinsIBA
06/2011
1Peroxidase (Myeloperoxidase)IBA
12/2010
1Interferon-gamma (Interferon, gamma)IBA
05/2010
1Pharmaceutical PreparationsIBA
02/2010

Therapy/Procedure

20Immunotherapy
01/2021 - 06/2002
17Therapeutics
10/2018 - 05/2004
4Drug Therapy (Chemotherapy)
01/2020 - 09/2013
3Duration of Therapy
06/2014 - 03/2011
2Hematopoietic Stem Cell Transplantation
10/2022 - 01/2022
2Secondary Prevention
02/2019 - 01/2018
1Transplantation
10/2022
1Consolidation Chemotherapy
11/2019
1Intravenous Injections
02/2019
1Stem Cell Transplantation
01/2018
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
09/2013
1Retreatment
07/2013
1Induction Chemotherapy
08/2010